Literature DB >> 16720923

Primary extranodal lymphomas of gastrointestinal localizations: a single institution 5-yr experience.

B Mihaljević1, R Nedeljkov-Jancić, V Vujicić, D Antić, S Janković, N Colović.   

Abstract

This study is aimed at comparison of patients with extranodal lymphomas based on pathohistological findings differences (MALT vs non-MALT) as well as regarding gastric and non-gastric localization, and determining the significance of clinical-laboratory parameters with respect to therapeutic response and length of survival. A total of 56 patients with extranodal non-Hodgkin's lymphomas of the gastrointestinal tract were evaluated over a 5-yr period. Regarding the localization of the disease, the stomach was most frequently affected, 39 patients (70%); followed by small and large intestines, 17 patients. As for the pathohistological findings, MALT lymphoma accounted for 70%, DLBCL 25%, while other subtypes accounted for 5%. Patients' distribution was analyzed according to CS based on both Ann Arbor and Lugano systems; however, the difference obtained between the groups was not statistically significant in both staging types of patients. Statistically significant difference in patients' distribution was not found with respect to IPI index, bone marrow infiltration, anemia, hypoalbuminemia, or histological subtype and localization. Difference in survival between patients according to the pathohistological type was not statistically significant also according to the type of the affected gastrointestinal tract organ. Statistical significance of difference according to survival probability was obtained based on age (survival is longer in patients over 55 yr of age); according to CS and according to Ann Arbor and Lugano classifications (the patients with lower CS live significantly longer); according to IPI index (the survival is significantly longer in patients with lower probability: IPI-0,1, and 2), as well as patients free of bone marrow infiltration whose survival is also significantly longer.

Entities:  

Mesh:

Year:  2006        PMID: 16720923     DOI: 10.1385/MO:23:2:225

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  36 in total

1.  Operative and conservative management of primary gastric lymphoma: interim results of a German multicenter study.

Authors:  N A Willich; G Reinartz; E J Horst; G Delker; B Reers; W Hiddemann; M Tiemann; R Parwaresch; B Grothaus-Pinke; J Kocik; P Koch
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-03-01       Impact factor: 7.038

Review 2.  Mucosa-associated lymphoid tissue lymphoma.

Authors:  Andrew Charles Wotherspoon; Ahmet Dogan; Ming-Qing Du
Journal:  Curr Opin Hematol       Date:  2002-01       Impact factor: 3.284

Review 3.  Diagnostic imaging evaluation of Hodgkin's disease and non-Hodgkin's lymphoma.

Authors:  R A Castellino
Journal:  Cancer       Date:  1991-02-15       Impact factor: 6.860

4.  Gastric lymphoma and Helicobacter pylori.

Authors:  P G Isaacson
Journal:  N Engl J Med       Date:  1994-05-05       Impact factor: 91.245

5.  Gastrointestinal malignant lymphomas of the mucosa-associated lymphoid tissue: factors relevant to prognosis.

Authors:  T Radaszkiewicz; B Dragosics; P Bauer
Journal:  Gastroenterology       Date:  1992-05       Impact factor: 22.682

6.  Conservative treatment of primary gastric low-grade B-cell lymphoma of mucosa-associated lymphoid tissue: predictive factors of response and outcome.

Authors:  Michaël Levy; Christiane Copie-Bergman; Catherine Traulle; Anne Lavergne-Slove; Nicole Brousse; Jean-François Flejou; A de Mascarel; François Hemery; Philippe Gaulard; Jean-Charles Delchier
Journal:  Am J Gastroenterol       Date:  2002-02       Impact factor: 10.864

Review 7.  Molecular diagnostics in low-grade gastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type after Helicobacter pylori eradication therapy.

Authors:  B Alpen; C Thiede; T Wündisch; E Bayerdörffer; M Stolte; A Neubauer
Journal:  Clin Lymphoma       Date:  2001-09

8.  Ongoing monoclonal B-cell proliferation is not common in gastric B-cell lymphoma after combined radiochemotherapy.

Authors:  Birgit Alpen; Rolf Kuse; Radzak Parwaresch; Hans Konrad Müller-Hermelink; Manfred Stolte; Andreas Neubauer
Journal:  J Clin Oncol       Date:  2004-08-01       Impact factor: 44.544

9.  Peripheral T-cell lymphomas of the intestine.

Authors:  A Chott; B Dragosics; T Radaszkiewicz
Journal:  Am J Pathol       Date:  1992-12       Impact factor: 4.307

10.  Primary gastrointestinal lymphoma: a 30-year review.

Authors:  D N Weingrad; J J Decosse; P Sherlock; D Straus; P H Lieberman; D A Filippa
Journal:  Cancer       Date:  1982-03-15       Impact factor: 6.860

View more
  4 in total

1.  Primary intestinal non-Hodgkin's lymphoma: a clinicopathologic analysis of 81 patients.

Authors:  Guo-Bao Wang; Guo-Liang Xu; Guang-Yu Luo; Hong-Bo Shan; Yin Li; Xiao-Yan Gao; Jian-Jun Li; Rong Zhang
Journal:  World J Gastroenterol       Date:  2011-11-07       Impact factor: 5.742

2.  Primary non-Hodgkin lymphomas in the small and large intestine: clinicopathological characteristics and management of 40 patients.

Authors:  Bo Li; Yuan-Kai Shi; Xiao-Hui He; Shuang-Mei Zou; Sheng-Yu Zhou; Mei Dong; Jian-Liang Yang; Peng Liu; Li-Yan Xue
Journal:  Int J Hematol       Date:  2008-05       Impact factor: 2.490

3.  Gastrointestinal lymphomas in a North American population: clinicopathologic features from one major Central-Midwestern United States tertiary care medical center.

Authors:  Joshua Warrick; Jingqin Luo; Diane Robirds; Julie Branson; John L Frater; Friederike Kreisel; Anjum Hassan; Tudung T Nguyen
Journal:  Diagn Pathol       Date:  2012-06-28       Impact factor: 2.644

4.  Consolidation Radiotherapy in Stage IE- IIE, Non-Bulky Primary Gastric Diffuse Large B-Cell Lymphoma with Post-Chemotherapy Complete Remission.

Authors:  Qiwen Li; Wei Li; Liang Wang; Weida Wang; Shaoqing Niu; Xiwen Bi; Hanyu Wang; Yujing Zhang
Journal:  PLoS One       Date:  2015-07-20       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.